CGTX
Cognition Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +49.4%
- EBIT
- +30.9%
- EPS
- +71.3%
- Free cash flow
- +42.4%
- Operating cash flow
- +42.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +63.9%
- EPS
- -58.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- +31.0%
- EBIT
- +11.4%
- Net income
- +30.9%
- EPS
- +62.4%
- Free cash flow
- +13.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026